Industry / Brazil
ANVISA Clamps Down On COX-2 Inhibitors
October 2008 | Industry NewsBrazilian regulator ANVISA is taking a more cautious stance on non-steroidal anti-inflammatory inhibitor drugs (NSAID) of cyclooxygenase (COX-2) in the wake of a three month review of their safety. ANVISA began reassessing the class of drugs in July, and has decided to implement a blanket reclassification of COX-2 inhibitors. A white C1 prescription will now be required for COX-2 inhibitors, while specific drugs face labelling changes or
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
